Amarin Corporation
Update in progressAMRN (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - General
Amarin Corporation plc is a pharmaceutical company focused on developing and commercializing cardiovascular therapies in the United States, Europe, and beyond. It markets Vascepa, a prescription omega-3 fatty acid used with diet to reduce triglycerides in adults with severe hypertriglyceridemia. Products are sold mainly through wholesalers and pharmacies. It collaborates with Mochida to develop and commercialize EPA-based products. Formerly Ethical Holdings plc; renamed in 1999. Established 1989, based in Dublin, Ireland.
Company score
- Sentiment
- -0.11
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- -0.15
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.03
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.07
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!